ReviewScience translational medicine2020
Priorities for developing respiratory syncytial virus vaccines in different target populations.
Review in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods.Molecular diversity · 2026Article
- A case of transient monoclonal plasma cell aberrancy following respiratory syncytial virus (RSV) vaccination.Journal of hematopathology · 2026Article
- Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.MedComm · 2024Review
- A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein.Nature communications · 2024Article
- Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy.Pharmaceutics · 2024Review
- Burden of respiratory syncytial virus diseases among under 5 children in Sub-Saharan Africa:Heliyon · 2023Article
- mRNA vaccines in disease prevention and treatment.Signal transduction and targeted therapy · 2023Review
- Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.NPJ vaccines · 2023Article
- Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study.Open forum infectious diseases · 2023Article
- Cross-protective antibodies against common endemic respiratory viruses.Nature communications · 2023Article
- Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia.Frontiers in immunology · 2023Article
- Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings.The Journal of infectious diseases · 2022Observational
- Article
- Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain.EMBO molecular medicine · 2022Article
- Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI.Vaccines · 2021Article
- Epidemiology and prevention of respiratory syncytial virus infections in children in Italy.Italian journal of pediatrics · 2021Review
- Implementation strategies for passive respiratory syncytial virus immunisation.The Lancet. Infectious diseases · 2021Article
- Aging and Options to Halt Declining Immunity to Virus Infections.Frontiers in immunology · 2021Review
- Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.BMC medicine · 2020Article
- The Application of Single-Cell RNA Sequencing in Vaccinology.Journal of immunology research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
The development of an effective vaccine against respiratory syncytial virus (RSV) has been hampered by major difficulties that occurred in the 1960s when a formalin-inactivated vaccine led to increased severity of RSV disease after acquisition of the virus in the RSV season after vaccination. Recent renewed efforts to develop a vaccine have resulted in about 38 candidate vaccines and monoclonal antibodies now in clinical development. The target populations for effective vaccination are varied and include neonates, young children, pregnant women, and older adults. The reasons for susceptibility to infection in each of these groups may be different and, therefore, could require different vaccine types for induction of protective immune responses, adding a further challenge for vaccine development. Here, we review the current knowledge of RSV vaccine development for these target populations and propose a view and rationale for prioritizing RSV vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.